Corcept Therapeutics | CORT - Assets


Corcept Therapeutics reported $836.65M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
ANI Pharmaceuticals USD 1.41B 65.15M Sep/2025
Ardelyx USD 486.17M 19.4M Sep/2025
Assertio Holdings USD 319.77M 46M Sep/2025
Aurora Cannabis CAD 756.86M 80.98M Sep/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Canopy Growth CAD 1.07B 165.17M Sep/2025
Corcept Therapeutics USD 836.65M 13.04M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Knight Therapeutics CAD 962.29M 16.93M Sep/2024
Lexicon Pharmaceuticals USD 225.58M 72.09M Jun/2025
Merck USD 129.55B 12.02B Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.3B 239.68M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Supernus Pharmaceuticals USD 1.42B 37.35M Sep/2025
TG Therapeutics USD 1.03B 322.41M Sep/2025